This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome


Gavrilova, S. I., Fedorova, Ia B., Gantman,, Kalyn, Ia B., Kolykhalov, I. V.


Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia I Meditsinskoĭ Promyshlennosti Rossiĭskoĭ Federatsii, Vserossiĭskoe Obshchestvo Nevrologov [I] Vserossiĭskoe Obshchestvo Psikhiatrov, Volume: 111, No.: 12, Pages.: 16-20

Year of Publication



The objective was to study efficacy and safety of ceraxon (citicoline) used perorally in dose 1000 mg daily in the treatment of cognitive disturbances in patients with amnesic type of mild cognitive impairment (MCI). Twenty patients, aged from 50 to 90 years, received ceraxon in dose 1000 mg twice a day during 90 days. The state of patients was assessed with a battery of scales and tests with the following statistical data analysis. The significant results on the clinical effect of the drug on cognitive disturbances and good tolerability of ceraxon have been obtained. The authors recommend ceraxon for long-term preventive treatment in high risk populations for Alzheimer’s disease.;


administration & dosage, adverse effects, aged, aged, 80 and over, alzheimer disease, citicoline, cytidine diphosphate choline, drug therapy, female, humans, male, middle aged, mild cognitive impairment, nootropic agents, prevention & control, syndrome, therapeutic use

Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Before and After Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions